Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
US11491147B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2017 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Oct 3, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reduction of resistance to the treatment, prevention, and/or diagnosis of diseases characterized by the formation of cancers. Embodiments include methods of treating cancer, comprising the steps of: providing a patient diagnosed with cancer with a therapeutic regime that includes at least one therapeutically effective dose of at least one agent that reduces the activity of at least one DNA damage/repair pathway. Other embodiments include methods of treating cancer, comprising the steps of: treating a patient diagnosed with cancer with a combination of therapeutic agents that includes at least one therapeutically effective anti-cancer agent and at least one compound that reduces the activity of at least one DNA damage/repair pathway. Yet other embodiments include methods of reducing resistance to a genotoxic therapeutic, comprising the steps of: treating a patient at least one therapeutically effective dose of at least one agent that reduces at least one DNA damage/repair pathway.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.